Q2 2026 revenues rose 10% year-over-year to $10.1B, with strong growth in key products and pipeline progress. GAAP EPS surged 65% to $4.37, while non-GAAP EPS rose 4% to $6.29. Full-year guidance projects continued revenue and EPS growth.Original document: Amgen Inc. [AMGN] SEC 8-K Current Report —…
Q2 2026 revenues rose 10% year-over-year to $10.1B, with strong growth in key products and pipeline progress. GAAP EPS surged 65% to $4.37, while non-GAAP EPS rose 4% to $6.29. Full-year guidance projects continued revenue and EPS growth.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
